Abstract:Introduction: Affecting ~1% of the world population, schizophrenia is known as one of the costliest and most burdensome diseases worldwide. Antipsychotic medications are the main treatment for schizophrenia to control psychotic symptoms and efficiently prevent new crises. However, due to poor compliance, 74% of patients with schizophrenia discontinue medication within 1.5 years, which severely affects recovery and prognosis. Through research on intra and interindividual variability based on a psychopathology–neuropsychology–neuroimage–genetics–physiology-biochemistry model, our main objective is to investigate an optimized and individualized antipsychotic-treatment regimen and precision treatment for first-episode schizophrenic patients. Methods and Analysis: The study is performed in 20 representative hospitals in China. Three subprojects are included. In subproject 1, 1,800 first-episode patients with schizophrenia are randomized into six different antipsychotic monotherapy groups (olanzapine, risperidone, aripiprazole, ziprasidone, amisulpride, and haloperidol) for an 8-week treatment. By identifying a set of potential biomarkers associated with antipsychotic treatment response, we intend to build a prediction model, which includes neuroimaging, epigenetics, environmental stress, neurocognition, eye movement, electrophysiology, and neurological biochemistry indexes. In subproject 2, apart from verifying the prediction model established in subproject 1 based on an independent cohort of 1,800 first-episode patients with schizophrenia, we recruit patients from a verification cohort who did not get an effective response after an 8-week antipsychotic treatment into a randomized double-blind controlled trial with minocycline (200 mg per day) and sulforaphane (3 tables per day) to explore add-on treatment for patients with schizophrenia. Two hundred forty participants are anticipated to be enrolled for each group. In subproject 3, we tend to carry out one trial to construct an intervention strategy for metabolic syndrome induced by antipsychotic treatment and another one to build a prevention strategy for patients at a high risk of metabolic syndrome, which combines metformin and lifestyle intervention. Two hundred participants are anticipated to be enrolled for each group. Ethics and Dissemination: The study protocol has been approved by the Medical Ethics committee of the Second Xiangya Hospital of Central South University (No. 2017027). Results will be disseminated in peer-reviewed journals and at international conferences. Trial Registration: This trial has been registered on Clinicalrials.gov (NCT03451734). The protocol version is V.1.0 (April 23, 2017).

Short-term antipsychotic treatment response in early-onset, typical-onset, and late-onset first episode schizophrenia

Protocol for a Pharmacogenomic Study on Individualised Antipsychotic Drug Treatment for Patients with Schizophrenia.

Efficacy and Safety of Long-Acting Risperidone on Early Onset Schizophrenia in Adolescent Patients

The Age of Onset and Cognitive Impairment at the Early Stage of Schizophrenia.

Epigenetic Clock Analysis of Blood Samples in Drug-Naive First-Episode Schizophrenia Patients.

Comparison of Clinical Characteristics and Treatment Efficacy in Childhood-Onset Schizophrenia and Adolescent-Onset Schizophrenia in Mainland China: A Retrospective Study.

Association of Telomere Length and Mitochondrial DNA Copy Number with Risperidone Treatment Response in First-Episode Antipsychotic-Naïve Schizophrenia

Gut Microbial Biomarkers for the Treatment Response in First-Episode, Drug-Naïve Schizophrenia: a 24-Week Follow-Up Study

Analysis of the Status of Drug Treatment in 746 Inpatients with Early-Onset Schizophrenia in China: a Retrospective Study.

Predictors of Outcome in Early Onset Schizophrenia: a 10-Year Follow-Up Study.

Incidence and factors associated of early non-response in first-treatment and drug-naïve patients with schizophrenia: a real-world study

Identification and treatment of individuals with childhood-onset and early-onset schizophrenia

Optimizing and Individualizing the Pharmacological Treatment of First-Episode Schizophrenic Patients: Study Protocol for a Multicenter Clinical Trial

Late‐onset and nonlate‐onset schizophrenia: A comparison of clinical characteristics in a multicenter study

Higher Required Dosage of Antipsychotics to Relieve the Symptoms of First-Onset Acute and Transient Psychotic Disorder (ATPD) Predicted the Subsequent Diagnostic Transition to Schizophrenia: A Longitudinal Study

Longitudinal Trajectory Analysis of Antipsychotic Response in Patients with Schizophrenia: 6-Week, Randomised, Open-Label, Multicentre Clinical Trial

Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?

Neurodevelopmental predictors of treatment response in schizophrenia and bipolar disorder

A comparison of clinical characteristics and course predictors in early‐ and childhood‐onset schizophrenia

Improvement of Social Functioning in Patients with First-Episode Schizophrenia Using Blonanserin Treatment: a Prospective, Multi-Centre, Single-Arm Clinical Trial

Comparative Study on Clinical and Neuropsychological Characteristics in Patients with Early-onset and Late-onset Schizophrenia